Med24
clinical-research 16. 11. 2026 • 2 min read • ClinicalTrials.gov (Essilor International)

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

Illustrasjon som viser sammenhengen mellom kortisol, hjerte, nyre og metabolske prosesser i forbindelse med CKM-sykdommer.

This study aims to demonstrate the non-inferiority of the Equinox System compared to the iLux 2020 System for the treatment of evaporative dry eye disease resulting from meibomian gland dysfunction (MGD). The research involves approximately 120 participants enrolled across a minimum of three and up to five sites within the United States.

Study Design and Procedures

The study’s duration is expected to be six months, with participant involvement spanning approximately four weeks, including pretreatment, treatment day, two-week, and four-week follow-up visits. The investigational therapy utilizes low-level light therapy (LLLT) in conjunction with manual expression of the meibomian glands. LLLT employs gentle light to stimulate cellular function, potentially repairing damaged cells and improving healthy cell function. It may also warm natural oils in the eyelids and reduce the presence of mites near the eyelashes. These effects are intended to support overall eye health and comfort.

Sponsored content

Treatment Protocol

Participants will be randomized to receive treatment using either the Equinox System (a red mask) or the iLux 2020 System. There is a 50% chance of receiving treatment with the Equinox System and a 50% chance of receiving treatment with the iLux 2020 System. During treatment, participants will be positioned in either the prone or supine position and will wear the red mask for 17 minutes. Protective eyewear is not required, and participants will be instructed to keep their eyes closed to ensure full application of the treatment to the upper and lower lids and the periorbital area. Immediately following the 17-minute treatment, the mask will be removed, and the meibomian glands will be manually expressed by a trained and qualified clinician.

Original Scientific Source
ClinicalTrials.gov (Essilor International)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
clinical-research

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

10. 11. 2026 Read article →
Advertisement